Coherus To Present Randomized Phase 2 Study Evaluating The Combination Of Casdozokitug, Toripalimab And Bevacizumab In Patients With Liver Cancer

Benzinga12/18 21:45

Biosimilars Market Industry Trends and Global Forecasts to 2035, Featuring Amgen, BIOCAD, Biocon, Celltrion, Coherus BioSciences, Eli Lilly, Fresenius Kabi, Pfizer, Sandoz and Teva Pharmaceuticals - ResearchAndMarkets.com

Businesswire12/10 22:48

Coherus BioSciences Price Target Raised to $6.00/Share From $4.00 by Baird

Dow Jones12/05 21:23

Coherus BioSciences Is Maintained at Outperform by Baird

Dow Jones12/05 21:23

Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Boosted 137% But Its Business Prospects Need A Lift Too

Simply Wall St12/04 20:21

HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target

Benzinga12/04 19:37